Street Calls of the Week
WARSAW - Zimmer Biomet Holdings, Inc. (NYSE and SIX:ZBH), a $19.6 billion medical technology company with impressive 71% gross margins, announced on Wednesday the full commercial launch of two new products designed for complex foot and ankle trauma procedures.
The medical technology company, which generated $7.8 billion in revenue over the last twelve months, has introduced the Gorilla Pilon Fusion Plating System and the Phantom TTC Trauma Nail, both now available to foot and ankle specialists in the United States.
The Gorilla Pilon Fusion Plating System provides a solution for primary tibiotalar fusion in patients with pilon fractures, which account for approximately 7% to 10% of all tibial fractures. The system features anatomically-contoured plates with region-specific thickness and tapered ends designed to reduce soft tissue disruption.
The Phantom TTC Trauma Nail, an expansion of the company’s existing Phantom TTC Nail platform, offers additional lengths and fixation capabilities for managing complex trauma cases, including pilon fractures requiring tibiotalocalcaneal fusion.
"The Gorilla Pilon Fusion System offers a lower-profile option that is anatomically contoured and enables stable fixation across both columns," said Dr. Clayton Bettin, Division Chief of Hospital Orthopedics at Campbell Clinic in Memphis, Tennessee, in the press release.
Both products were developed in collaboration with orthopedic surgeons and feature precision-engineered instrumentation designed for surgical efficiency.
Albert DaCosta, Global President Foot and Ankle at Zimmer Biomet, stated that these new solutions help address patient populations that have historically had few reliable options.
Zimmer Biomet, with over 90 years in the medical technology industry, operates in more than 25 countries with sales in over 100 countries. According to InvestingPro analysis, the company maintains a strong financial health rating and has consistently paid dividends for 14 consecutive years. InvestingPro’s Fair Value analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report, which offers deep-dive analysis of this and 1,400+ other top US stocks.
In other recent news, Zimmer Biomet Holdings, Inc. has completed its acquisition of Monogram Technologies Inc., an AI-driven orthopedic robotics company. This acquisition is set to integrate Monogram’s semi-autonomous and fully autonomous robotic technologies into Zimmer Biomet’s orthopedic solutions. Additionally, Japan’s Pharmaceutical and Medical Devices Agency has approved Zimmer Biomet’s iTaperloc Complete and iG7 Hip System, marking the world’s first orthopedic implants with Iodine Technology designed to inhibit bacterial adhesion.
Stifel has raised its price target for Zimmer Biomet to $118, maintaining a Buy rating after discussions with orthopedic surgeons about the company’s products. Meanwhile, Rothschild Redburn initiated coverage with a Buy rating and a $130 price target, citing the company’s potential for organic growth in the orthopedic market. JMP Securities has also maintained its Market Outperform rating and a $125 price target following Zimmer Biomet’s strong second-quarter results, which showed a 3% revenue growth year-over-year. These developments reflect Zimmer Biomet’s ongoing efforts to innovate and expand in the orthopedic industry.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.